GlassScriptPhysician profile
Janelle C Thomas
NPI 1114683877
$270.20
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $40.32 · 2022: $230.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $42.64 | 2022 | |
| Dendreon Pharmaceuticals LLC | $41.57 | 2022 | |
| 180 Medical, INC. | $29.02 | 2022 | |
| Antares Pharma, INC. | $25.82 | 2021-2022 | |
| Baudax Bio INC. | $24.66 | 2022 | |
| Boston Scientific Corporation | $17.31 | 2022 | |
| Axonics, INC. | $17.19 | 2022 | |
| Olympus America INC. | $15.79 | 2022 | |
| Endo Pharmaceuticals INC. | $14.62 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $13.95 | 2021 | |
| Teleflex LLC | $13.85 | 2022 | |
| Clarus Therapeutics INC. | $13.78 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janelle Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.